reversible SARS-CoV-2 3CLpro inhibitor - Shionogi Pharmaceutical

reversible SARS-CoV-2 3CLpro inhibitor

Ph. II/III candidate for COVID-19

virtual + HTS MS screen, SBDD

bioRxiv

Shionogi Pharmaceutical

S-217622 is the first oral, non-covalent, non-peptidic SARS-CoV-2 3CL (main protease) inhibitor clinical candidate, currently in Ph. II/III trials as a once-daily oral treatment for COVID-19. Unlike paxlovid, the…


 this content is exclusive to
Premium members

Upgrade to a Premium Drug Hunter membership to unlock the full content and start reading now.